September 2005
Worldwide Biotech;Sep2005, Vol. 17 Issue 9, p7
Trade Publication
Focuses on Incyte Corporation's randomized double-blind phase IIb trial of Reverset in treatment-experienced HIV infected patients. Number of patients and clinical sites involved in the study; Preliminary results from the trial on Reverset's efficacy; Stages of the study's protocol.


Related Articles

  • Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals. Clifford, David B.; Evans, Scott; Yijun Yang; Acosta, Edward P.; Goodkin, Karl; Tashima, Karen; Simpson, David; Dorfman, David; Ribaudo, Heather; Gulick, Roy M. // Annals of Internal Medicine;11/15/2005, Vol. 143 Issue 10, p714 

    Background: Efavirenz is a commonly used antiretroviral drug that causes neurologic side effects in more than 50% of patients. Objective: To characterize efavirenz-associated neurologic symptoms in a randomized, controlled study of initial antiretroviral treatment. Design: Substudy of a...

  • Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Conant, M. A.; Schacker, T. W.; Murphy, R. L.; Gold, J.; Crutchfield, L. T.; Crooks, R. J.; International Valaciclovir HSV Study Group // International Journal of STD & AIDS;Jan2002, Vol. 13 Issue 1, p12 

    Our objective was to evaluate valaciclovir for anogenital herpes in HIV-infected individuals using 2 controlled trials conducted before highly active antiretroviral therapy (HAART) was used. In Study 1, 1062 patients (CD4+ > or = 100 cells/mm(3)) received suppressive valaciclovir or aciclovir...

  • A Randomized Trial of Directly Administered Antiretroviral Therapy and Adherence Case Management Intervention. Wohl, Amy Rock; Garland, Wendy H.; Valencia, Rosa; Squires, Kathleen; Witt, Mallory D.; Kovacs, Andrea; Larsen, Robert; Hader, Shannon; Anthony, Monique-Nicole; Weidle, Paul J. // Clinical Infectious Diseases;6/1/2006, Vol. 42 Issue 11, p1619 

    Background. A randomized, controlled trial was conducted to evaluate the impact of a directly administered antiretroviral therapy program (DAART) and intensive adherence case management (IACM) intervention on virologic and immunologic response to highly active antiretroviral therapy (HAART)...

  • Resistance study to re-evaluate HAART. Kenyon, Georgina // Nature Medicine;May2001, Vol. 7 Issue 5, p515 

    Reports on the international trial to determine the effectiveness of the treatment for AIDS patients for failure of triple therapy on them. Development of HIV resistance to antiretroviral therapy (HAART); Increase in the global management of drug regime; Evaluation of the benefits for the...

  • Long-Term Responses to Treatment including Ritonavir or Nelfinavir in HIV-1-Infected Children. Nadal, D.; Steiner, F.; Cheseaux, J.-J.; Lazarevitch, C.-A.Wyler; Aebi, C.; Kind, C.; Rudin, C. // Infection;Oct2000, Vol. 28 Issue 5, p287 

    Background: Knowledge concerning the long-term antiretroviral and immunological efficacy of protease inhibitors in children is limited. Patients and Methods: An open-label, prospective, multicenter clinical trial was conducted over a period of 72 weeks in Switzerland. 60 HIV-1 infected children...

  • Tenofovìr may linger in the body for up to three weeks. Appleby, Jason // HIV Australia;Jul-Sep2005, Vol. 5 Issue 1, p27 

    Discusses research being done on the possible interaction of antiviral agents tenofovir and didanosine in HIV-infected patients. Reference to a study by A. Pruvost et al published in the May 2005 issue of "Antimicrobial Agents and Chemotherapy"; Possibility of drug resistance following...

  • TREATMENT BRIEFS.  // HIV Australia;2007, Vol. 7 Issue 1, p41 

    The article focuses on two international clinical trials of the drug interleukin-2 (IL-2, Proleukin) in Human Immunodeficiency Virus (HIV) afflicted people which had produced no result. IL-2 is reportedly a natural substance produced by T-cells that stimulates the production of CD4 T-cells. The...

  • A Prospective, Randomized Trial of Structured Treatment Interruption for Patients with Chronic HIV Type 1 Infection. Cardiello, Peter G.; Hassink, Elly; Ananworanich, Jintanat; Srasuebkul, Preeyaporn; Samor, Lanka; Mahanontharit, Apicha; Ruxrunqtham, Kiat; Hirschel, Bernard; Lange, Joep; Phanuphak, Praphan; Cooper, David A. // Clinical Infectious Diseases;2/15/2005, Vol. 40 Issue 4, p594 

    Background. Structured treatment interruption was evaluated in 74 patients who had been retreated with antiretrovirals, consisting of 2 nucleoside reverse-transcriptase inhibitors (NRTIs) for 1 year followed by 3 years of highly active antiretroviral therapy containing a protease inhibitor....

  • Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study. Manuel, Oriol; Husain, Shahid; Kumar, Deepali; Zayas, Carlos; Mawhorter, Steve; Levi, Marilyn E.; Kalpoe, Jayant; Lisboa, Luiz; Ely, Leticia; Kaul, Daniel R.; Schwartz, Brian S.; Morris, Michele I.; Ison, Michael G.; Yen-Lieberman, Belinda; Sebastian, Anthony; Assi, Maha; Humar, Atul // Clinical Infectious Diseases;Mar2013, Vol. 56 Issue 6, p817 

    In high-risk solid-organ transplant recipients receiving antiviral prophylaxis, the measurement of specific cell-mediated immunity using the Quantiferon assay appropriately stratified the individual risk of developing subsequent cytomegalovirus disease.Background. Cytomegalovirus (CMV) disease...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics